Organon Pharma Indonesia Tbk PT banner
O

Organon Pharma Indonesia Tbk PT
IDX:SCPI

Watchlist Manager
Organon Pharma Indonesia Tbk PT
IDX:SCPI
Watchlist
Price: 29 000 IDR Market Closed
Market Cap: Rp104.4B

Balance Sheet

Balance Sheet Decomposition
Organon Pharma Indonesia Tbk PT

Balance Sheet
Organon Pharma Indonesia Tbk PT

Rotate your device to view
Balance Sheet
Currency: IDR
Dec-2001 Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
1 538
2 950
3 231
1 508
666
1 693
4 732
6 034
2 231
2 663
28 209
17 787
18 014
35 470
9 201
68 229
22 097
23 196
27 837
44 492
151 065
164 081
123 151
114 187
Cash
0
0
0
4
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash Equivalents
1 538
2 950
3 231
1 504
659
1 686
4 725
6 034
2 231
2 663
28 209
17 787
18 014
35 470
9 201
68 229
22 097
23 196
27 837
44 492
151 065
164 081
123 151
114 187
Short-Term Investments
0
0
0
50
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Receivables
16 818
16 947
14 827
14 628
25 245
9 235
45 486
49 292
54 913
61 813
88 052
113 042
216 491
648 684
784 337
304 648
336 363
326 958
256 188
460 826
225 623
175 047
467 390
338 080
Accounts Receivables
16 490
16 803
14 597
14 524
24 674
8 895
45 101
48 781
54 425
60 353
84 036
74 560
141 038
395 620
542 513
251 686
286 649
310 886
241 592
451 031
215 118
169 431
463 813
329 660
Other Receivables
328
144
230
104
571
340
385
511
488
1 460
4 016
38 482
75 453
253 064
241 824
52 962
49 714
16 071
14 596
9 794
10 505
5 617
3 577
8 420
Inventory
18 893
13 948
15 016
16 305
19 511
45 032
37 527
91 862
102 531
111 097
115 368
105 255
260 927
324 082
407 900
388 137
347 357
456 974
510 327
278 895
151 326
378 501
386 646
589 934
Other Current Assets
3 359
2 078
1 875
2 578
2 044
5 738
3 077
6 056
3 481
11 090
25 701
27 486
27 687
50 784
60 062
383 709
392 427
536 192
320 449
328 779
235 870
342 440
169 437
288 901
Total Current Assets
40 608
35 923
34 949
35 068
47 516
61 698
90 822
153 243
163 155
186 663
257 330
263 570
523 119
1 059 020
1 261 501
1 144 724
1 098 245
1 343 320
1 114 801
1 112 991
763 884
1 060 069
1 146 623
1 331 103
PP&E Net
15 870
18 936
20 096
20 456
23 302
30 375
33 125
35 182
35 871
30 687
41 425
164 522
214 209
247 072
238 683
234 101
244 203
279 003
287 490
290 782
297 438
282 580
265 228
294 409
PP&E Gross
15 870
18 936
20 096
20 456
23 302
30 375
33 125
35 182
35 871
30 687
41 425
164 522
214 209
0
0
0
0
0
0
0
0
0
0
0
Accumulated Depreciation
11 177
13 828
15 128
18 083
20 265
20 671
24 558
25 435
29 526
30 686
29 801
32 276
41 243
0
0
0
0
0
0
0
0
0
0
0
Note Receivable
0
0
0
0
0
3 006
132
6 896
172
4 513
0
0
0
0
0
0
0
0
0
8 421
0
0
0
0
Other Long-Term Assets
5 802
6 397
2 708
2 980
3 205
3 794
4 487
4 206
7 059
11 893
13 763
12 406
9 074
17 306
10 564
14 259
11 657
13 380
15 413
186 088
150 838
18 778
9 495
10 460
Total Assets
62 280
N/A
61 256
-2%
57 753
-6%
58 504
+1%
74 023
+27%
98 874
+34%
128 565
+30%
199 526
+55%
206 257
+3%
233 756
+13%
312 519
+34%
440 498
+41%
746 402
+69%
1 323 398
+77%
1 510 748
+14%
1 393 084
-8%
1 354 104
-3%
1 635 703
+21%
1 417 704
-13%
1 598 282
+13%
1 212 161
-24%
1 361 427
+12%
1 421 347
+4%
1 635 971
+15%
Liabilities
Accounts Payable
14 009
9 563
8 141
3 766
2 981
4 069
7 044
34 840
13 228
26 983
35 775
30 707
62 091
220 239
219 097
108 100
182 775
37 243
84 849
278 937
151 439
240 949
493 142
529 469
Accrued Liabilities
219
1 357
1 036
1 133
2 782
3 025
4 814
6 993
7 050
18 705
17 017
17 244
87 938
72 727
124 356
12 106
15 602
18 165
19 509
17 200
37 992
94 828
36 699
31 672
Short-Term Debt
40 900
44 000
39 000
42 500
59 581
86 034
102 000
128 810
152 173
155 446
0
0
0
0
18 862
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
598 399
624
547 592
358 533
0
351 947
1 826
2 135
2 484
2 877
Other Current Liabilities
2 917
3 148
3 995
4 317
3 034
561
4 375
1 375
4 633
8 909
15 299
49 033
50 710
142 840
28 401
93 585
102 481
85 473
83 243
92 530
13 092
5 867
10 873
4 955
Total Current Liabilities
58 045
58 069
52 172
51 716
68 378
93 688
118 233
172 018
177 085
210 043
68 090
96 984
200 739
435 806
989 115
214 416
848 450
499 414
187 602
740 613
204 350
343 779
543 198
568 973
Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
892
1 225
1 008
403 632
920 240
115 865
599 857
574 947
0
7 751
5 616
3 186
255
Other Liabilities
0
0
0
4 886
4 607
6 640
8 533
19 160
9 504
11 590
222 832
325 336
534 047
930 441
17 129
24 159
32 639
34 026
38 155
25 459
27 508
26 695
34 516
33 739
Total Liabilities
58 045
N/A
58 069
+0%
52 172
-10%
56 601
+8%
72 985
+29%
100 328
+37%
126 767
+26%
191 178
+51%
186 589
-2%
221 633
+19%
290 922
+31%
423 212
+45%
736 011
+74%
1 367 254
+86%
1 409 876
+3%
1 158 815
-18%
996 954
-14%
1 133 297
+14%
800 704
-29%
766 072
-4%
239 608
-69%
376 090
+57%
580 899
+54%
602 967
+4%
Equity
Common Stock
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
3 600
Retained Earnings
539
508
1 885
1 793
2 657
5 150
2 581
4 135
14 924
6 881
18 539
30 906
48 704
111 165
95 200
228 597
350 125
492 666
607 261
822 470
942 847
955 631
810 742
1 003 298
Additional Paid In Capital
0
0
0
0
0
0
684
613
1 144
1 642
1 721
1 873
2 072
2 072
2 072
2 072
3 425
6 139
6 139
6 139
26 106
26 106
26 106
26 106
Other Equity
96
96
96
96
96
96
96
0
0
0
34 815
42 719
53 423
61 636
0
0
0
0
0
0
0
0
0
0
Total Equity
4 235
N/A
3 187
-25%
5 581
+75%
1 902
-66%
1 038
-45%
1 454
N/A
1 799
N/A
8 349
+364%
19 668
+136%
12 123
-38%
21 597
+78%
17 286
-20%
10 391
-40%
43 857
N/A
100 872
N/A
234 269
+132%
357 150
+52%
502 405
+41%
617 000
+23%
832 209
+35%
972 552
+17%
985 337
+1%
840 448
-15%
1 033 004
+23%
Total Liabilities & Equity
62 280
N/A
61 256
-2%
57 753
-6%
58 504
+1%
74 023
+27%
98 874
+34%
128 565
+30%
199 526
+55%
206 257
+3%
233 756
+13%
312 519
+34%
440 498
+41%
746 402
+69%
1 323 398
+77%
1 510 748
+14%
1 393 084
-8%
1 354 104
-3%
1 635 703
+21%
1 417 704
-13%
1 598 282
+13%
1 212 161
-24%
1 361 427
+12%
1 421 347
+4%
1 635 971
+15%
Shares Outstanding
Common Shares Outstanding
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett